Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years
Open accessThe DOI matches its Crossref record; 195 of the 196 references it cites were found in a registry or an index.
Abstract
To date, pharmacological treatments for mood and anxiety disorders and for drug dependence show limited efficacy, leaving a large number of patients suffering severe and persistent symptoms. Preliminary studies in animals and humans suggest that ayahuasca, psilocybin and lysergic acid diethylamide (LSD) may have antidepressive, anxiolytic, and antiaddictive properties. Thus, we conducted a systematic review of clinical trials published from 1990 until 2015, assessing these therapeutic properties. Electronic searches were performed using the PubMed, LILACS, and SciELO databases. Only clinical trials published in peer-reviewed journals were included. Of these, 151 studies were identified, of which six met the established criteria. Reviewed studies suggest beneficial effects for treatment-resistant depression, anxiety and depression associated with life-threatening diseases, and tobacco and alcohol dependence. All drugs were well tolerated. In conclusion, ayahuasca, psilocybin and LSD may be useful pharmacological tools for the treatment of drug dependence, and anxiety and mood disorders, especially in treatment-resistant patients. These drugs may also be useful pharmacological tools to understand psychiatric disorders and to develop new therapeutic agents. However, all studies reviewed had small sample sizes, and half of them were open-label, proof-of-concept studies. Randomized, double-blind, placebo-controlled studies with more patients are needed to replicate these preliminary findings.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“they also appear to have broad therapeutic potential, demonstrating efficacy for treating depression, post-traumatic stress disorder (PTSD), anxiety disorders, substance abuse disorder, and alcohol use disorder, among others”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [171]
In the citing paper
“these medicines have demonstrated efficacy across a range of neuropsychiatric disorders including depression, PTSD, and addiction (156, 168–172)”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [171]
In the citing paper
“Most of these studies however suffer from low methodological validity and are mostly open-label, yet they have yielded preliminary evidence for the capacity of psychedelic substances for treating addiction, depression, anxiety, and eating disorders (29–35).”
From Examining the Potential Synergistic Effects Between Mindfulness Training and Psychedelic-Assisted Therapy (2021) · cites this paper as [31]
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Wang, G., Ma, R., Qiao, G., Wada, K., Aizawa, Y., & Satoh, T. (2015) · Integrative Medicine International · doi:10.1159/000368408 · Cited by 18,657
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684
Drug harms in the UK: a multicriteria decision analysis
Nutt, D. J., King, L. A., & Phillips, L. D. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61462-6 · Cited by 1,681
Carhart-Harris, R. L., Leech, R., Hellyer, P. J., Shanahan, M., Feilding, A., Tagliazucchi, E., Chialvo, D. R., & Nutt, D. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00020 · Cited by 1,252
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119598109 · Cited by 1,172
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151
Research works printed but not linked: 16
- Furst P., 1994, Alucinógenos y cultura
- Grob C., 1998, Heffter Rev Psychedelic Res, 1, 8
- Grof S., 2001, LSD psychotherapy
- Halpern J., 2008, Med Sci Monit, 14, SR15
- Harner M., 1976, Alucinógenos y chamanismo
- Hintzen A., 2010, The pharmacology of lysergic acid diethylamide: a critical review
- Hofmann A., 2005, LSD: my problem child
- House R., 1997, NIDA Res Monogr, 173, 175
- Labate B., 2009, Ayahuasca religions: a comprehensive bibliography and critical essays
- Lima L., 2006, Ärztez Naturheilverfahren, 47, 476
- Ott J., 1994, Ayahuasca analogues: pangaean entheogens
- Ott J., 2004, Pharmacotheon: drogas enteogénicas, sus fuentes vegetales y su historia
- Réus G., 2012, Depress Res Treat, 2012, 987397
- Schultes R., 1986, Am Indig, 46, 9
- Schultes R., 1998, Heffter Rev Psychedel Res, 1, 1
- Sos P., 2013, Neuro Endocrinol Lett, 34, 287
Cited by
Items 301–307 of 307
dos Santos, J. C. C., Bolan, S. J., da Silva, G. L., Viana, G. L., Rico, E. P., & Gonçalves, C. L. (2026) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2026.06.035
Lodetti, G., de Bitencourt, R. M., Inserra, A., Redivo, H., Teixeira, A. G., de Farias, A. C. S., Pickler, K. D. P., Rohling, J. P. V., Endler, A. T., Zampronio, E. P., et al. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111817
Deconstruction of lysergic acid diethylamide
Basargin, A. G., Domokos, A., Hennessey, J. J., Aarrestad, I. K., Sambyal, R., Khatib, Y. A., Krüger, J., Dunlap, L. E., Carter, S. J., Rebek, I. A., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2603412123
“Agonists of 5 - HT2A and 5 - HT2C receptors, such as LSD, produce several therapeutic effects (7, 8) while agonism of 5 - HT2B receptors is believed to increase risk for cardiac valvulopathy (9).”
Lodetti, G., Redivo, H., Teixeira, A. G., de Farias, A. C. S., Pacagnan, L. D. O., Rohling, J. P. V., Endler, A. T., Zampronio, E. P., de Souza, D. D. P., Assis, V. F., et al. (2026) · Journal of Neural Transmission · doi:10.1007/s00702-026-03287-w · Cited by 1
Huang, R., Yu, J., Zhuang, B., Yan, Z., Wei, G., Zhang, L., & Zhang, F. (2026) · Organic Process Research & Development · doi:10.1021/acs.oprd.6c00343
Salud intercultural en Pastaza: regulación del uso de plantas medicinales y de la ayahuasca
Iglesias-Quintana, J. X., Jiménez-Montenegro, J. M., Marfetan-Marfetan, V. D. R., & Piñas-Piñas, L. F. (2026) · Verdad y Derecho. Revista Arbitrada de Ciencias Jurídicas y Sociales. · doi:10.62574/n08gyqka
Uso inadecuado de la ayahuasca y sus impactos en la salud: percepción de consumidores
Illicachi-Erazo, A. M., & Toapanta-Amores, D. A. (2026) · Verdad y Derecho. Revista Arbitrada de Ciencias Jurídicas y Sociales. · doi:10.62574/g9gn9z5t
Metadata
- Authors
- dos Santos, R. G., Osório, F. L., Crippa, J. A. S., Riba, J., Zuardi, A. W., & Hallak, J. E. C.
- Affiliations
- Departamento de Neurociências e Ciências do Comportamento, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Hospital das Clínicas, Terceiro Andar, Av. Bandeirantes, 3900, Ribeirão Preto, São Paulo, Brazil
- Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, SP, Brazil National Institute for Translational Medicine (INCT-TM), CNPq, Brazil
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (BR)
- Centre d’Investigació de Medicaments, Servei de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
- Venue
- Therapeutic Advances in Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2016-03-18
- Volume
- 6
- Issue
- 3
- Pages
- 193-213
- ISSN
- 2045-1253 (ISSN-L)
- 2045-1261
- PMC
- PMC4910400
- OpenAlex
- W2325558246
- Cited by
- 306
- References
- 196
- Citations by year
- 2026: 18 · 2025: 17 · 2024: 50 · 2023: 28 · 2022: 32 · 2021: 44 · 2020: 35 · 2019: 27 · 2018: 29 · 2017: 20 · 2016: 5
- FWCI
- 4.00
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Therapeutic Advances in Psychopharmacology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Keywords
- ayahuasca, psilocybin, lysergic acid diethylamide, antidepressant effects, anxiolytic effects, treatment-resistant depression, anxiety disorders, drug addiction, tobacco dependence, alcoholism, psychedelics, mood disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.